These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 25559951)

  • 41. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigating the link between epithelial-mesenchymal transition and the cancer stem cell phenotype: A mathematical approach.
    Turner C; Kohandel M
    J Theor Biol; 2010 Aug; 265(3):329-35. PubMed ID: 20648969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype.
    Wang HJ; Guo YQ; Tan G; Dong L; Cheng L; Li KJ; Wang ZY; Luo HF
    J Cell Biochem; 2013 Oct; 114(10):2248-57. PubMed ID: 23606360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypoxia-inducible factor 1 and breast cancer metastasis.
    Liu ZJ; Semenza GL; Zhang HF
    J Zhejiang Univ Sci B; 2015 Jan; 16(1):32-43. PubMed ID: 25559953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug Resistance Driven by Cancer Stem Cells and Their Niche.
    Prieto-Vila M; Takahashi RU; Usuba W; Kohama I; Ochiya T
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
    Sousa B; Ribeiro AS; Paredes J
    Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity.
    Hong D; Fritz AJ; Zaidi SK; van Wijnen AJ; Nickerson JA; Imbalzano AN; Lian JB; Stein JL; Stein GS
    J Cell Physiol; 2018 Dec; 233(12):9136-9144. PubMed ID: 29968906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential.
    Roy S; Sunkara RR; Parmar MY; Shaikh S; Waghmare SK
    Front Biosci (Landmark Ed); 2021 Jan; 26(2):238-265. PubMed ID: 33049669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting Stemness: Implications for Precision Medicine in Breast Cancer.
    Liang ZM; Chen Y; Luo ML
    Adv Exp Med Biol; 2017; 1026():147-169. PubMed ID: 29282683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of chromatin accessibility domains in human breast cancer stem cells.
    Hardy K; Wu F; Tu W; Zafar A; Boulding T; McCuaig R; Sutton CR; Theodoratos A; Rao S
    Nucleus; 2016; 7(1):50-67. PubMed ID: 26962893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging Mechanisms by which EMT Programs Control Stemness.
    Wilson MM; Weinberg RA; Lees JA; Guen VJ
    Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of cancer stem cells in developing therapeutic resistance in oral cancer.
    Naik PP; Das DN; Panda PK; Mukhopadhyay S; Sinha N; Praharaj PP; Agarwal R; Bhutia SK
    Oral Oncol; 2016 Nov; 62():122-135. PubMed ID: 27865365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells.
    Pourmahdi M; Saber A; Rajabi A; Abdolahi S; Ebrahimi P; Safaralizadeh R
    Curr Stem Cell Res Ther; 2021; 16(7):877-887. PubMed ID: 33563177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptomic and epigenetic analysis of breast cancer stem cells.
    Li G; Wang D; Ma W; An K; Liu Z; Wang X; Yang C; Du F; Han X; Chang S; Yu H; Zhang Z; Zhao Z; Zhang Y; Wang J; Sun Y
    Epigenomics; 2018 Jun; 10(6):765-783. PubMed ID: 29480027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reprogramming to developmental plasticity in cancer stem cells.
    O'Brien-Ball C; Biddle A
    Dev Biol; 2017 Oct; 430(2):266-274. PubMed ID: 28774727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer.
    Ishiwata T
    Pathol Int; 2016 Nov; 66(11):601-608. PubMed ID: 27510923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer Stem Cells: An Ever-Hiding Foe.
    Wilczyński JR
    Exp Suppl; 2022; 113():219-251. PubMed ID: 35165866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epithelial-mesenchymal transition in breast cancer progression and metastasis.
    Wang Y; Zhou BP
    Chin J Cancer; 2011 Sep; 30(9):603-11. PubMed ID: 21880181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.